Results 191 to 200 of about 42,546 (247)

Natural Products as GPCR-Targeting Antidepressant Candidates: Advances and Opportunities. [PDF]

open access: yesPharmaceuticals (Basel)
Li H   +8 more
europepmc   +1 more source

Inhibition of Monoacylglycerol Lipase Suppresses Lipopolysaccharide-Enhanced Melanoma Proliferation and Migration. [PDF]

open access: yesCancers (Basel)
Almutairi F   +9 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

The Cannabinoid CB1 Receptor in Schizophrenia

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021
Converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may be involved in the pathophysiology of schizophrenia and suggest that the cannabinoid CB1 receptor may be a potential therapeutic target.
Faith Borgan   +2 more
openaire   +3 more sources

Assay of CB1 Receptor Binding

2022
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both the central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be ...
Gasperi V, Savini I, Catani MV
openaire   +3 more sources

The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940)

Behavioural Pharmacology, 2005
It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory animals, cannabinoid CB1 receptor antagonism decreases motivation for palatable foods, and most recently, the CB1 receptor antagonist SR141716A, or rimonabant (Acomplia), was reported to produce weight loss in obese human ...
S J, Ward, L A, Dykstra
openaire   +2 more sources

Home - About - Disclaimer - Privacy